Wednesday, October 14, 2026

Canadian National Railway Company Already 4% Up, Almost Hour Before The NYSE Open

Canadian National Railway Company Already 4% Up, Almost  Hour Before The NYSE Open

(VIANEWS) - The NYSE opens in less than hour and Canadian National Railway Company's pre-market value is already 4.99% up.

Canadian National Railway Company's last close was $129.96, 1.63% under its 52-week high of $132.12.

The last session, NYSE ended with Canadian National Railway Company (CNI) rising 0.92% to $129.96. NYSE rose 0.62% to $17,974.06, following the last session's upward trend on what was a somewhat up trend trading session.

About Canadian National Railway Company

Canadian National Railway Company, together with its subsidiaries, engages in the rail, intermodal, trucking, and marine transportation and logistics business in Canada and the United States. The company provides rail services, which include equipment, custom brokerage services, transloading and distribution, business development and real estate, and private car storage services; and intermodal services, such as temperature controlled cargo, port partnerships, and logistics parks. It offers trucking services, such as door-to-door services, import and export dray, interline services, and specialized services, comprising flatbed trucks, on-deck mobile transport trays, expedited cargo, and permit/overweight services; and supply chain services. It serves automotive, coal, fertilizers, temperature controlled cargo, forest products, dimensional, grain, metal and minerals, petroleum and chemicals, consumer goods, and third party logistics applications. The company operates a rail network of approximately 20,000 route-miles of track and shipping spanning. Canadian National Railway Company was incorporated in 1919 and is headquartered in Montreal, Canada.

Earnings Per Share

As for profitability, Canadian National Railway Company has a trailing twelve months EPS of $6.31.

PE Ratio

Canadian National Railway Company has a trailing twelve months price to earnings ratio of 20.6. Meaning, the purchaser of the share is investing $20.6 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.11%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Mar 6, 2024, the estimated forward annual dividend rate is 2.5 and the estimated forward annual dividend yield is 1.94%.

Growth Estimates Quarters

The company's growth estimates for the current quarter is a negative 6.5% and positive 11.5% for the next.

Moving Average

Canadian National Railway Company's worth is higher than its 50-day moving average of $126.99 and way above its 200-day moving average of $117.44.

More news about Canadian National Railway Company (CNI).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com